540 related articles for article (PubMed ID: 32493197)
1. Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
Tabassum T; Azeem SM; Muwonge AN; Frey KM
Curr HIV Res; 2020; 18(4):283-291. PubMed ID: 32493197
[TBL] [Abstract][Full Text] [Related]
2. Structure-based methods to predict mutational resistance to diarylpyrimidine non-nucleoside reverse transcriptase inhibitors.
Azeem SM; Muwonge AN; Thakkar N; Lam KW; Frey KM
J Mol Graph Model; 2018 Jan; 79():133-139. PubMed ID: 29156381
[TBL] [Abstract][Full Text] [Related]
3. Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.
Smith SJ; Pauly GT; Akram A; Melody K; Ambrose Z; Schneider JP; Hughes SH
J Acquir Immune Defic Syndr; 2016 Aug; 72(5):485-91. PubMed ID: 27124362
[TBL] [Abstract][Full Text] [Related]
4. Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates.
Asante-Appiah E; Lai J; Wan H; Yang D; Martin EA; Sklar P; Hazuda D; Petropoulos CJ; Walworth C; Grobler JA
Antimicrob Agents Chemother; 2021 Nov; 65(12):e0121621. PubMed ID: 34570651
[TBL] [Abstract][Full Text] [Related]
5. Cryo-EM structures of wild-type and E138K/M184I mutant HIV-1 RT/DNA complexed with inhibitors doravirine and rilpivirine.
Singh AK; De Wijngaert B; Bijnens M; Uyttersprot K; Nguyen H; Martinez SE; Schols D; Herdewijn P; Pannecouque C; Arnold E; Das K
Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2203660119. PubMed ID: 35858448
[TBL] [Abstract][Full Text] [Related]
6. Novel broad-spectrum thiourea non-nucleoside inhibitors for the prevention of mucosal HIV transmission.
D'Cruz OJ; Uckun FM
Curr HIV Res; 2006 Jul; 4(3):329-45. PubMed ID: 16842085
[TBL] [Abstract][Full Text] [Related]
7. Structure-based non-nucleoside inhibitor design: Developing inhibitors that are effective against resistant mutants.
Smith SJ; Pauly GT; Hewlett K; Schneider JP; Hughes SH
Chem Biol Drug Des; 2021 Jan; 97(1):4-17. PubMed ID: 32743937
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
Yang J; Chen W; Kang D; Lu X; Li X; Liu Z; Huang B; Daelemans D; Pannecouque C; De Clercq E; Zhan P; Liu X
Eur J Med Chem; 2016 Feb; 109():294-304. PubMed ID: 26802545
[TBL] [Abstract][Full Text] [Related]
9. Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors.
La Regina G; Coluccia A; Silvestri R
Antivir Chem Chemother; 2010 Aug; 20(6):213-37. PubMed ID: 20710063
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs.
Wang Z; Yu Z; Kang D; Zhang J; Tian Y; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
Bioorg Med Chem; 2019 Feb; 27(3):447-456. PubMed ID: 30606670
[TBL] [Abstract][Full Text] [Related]
11. In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.
Saladini F; Giammarino F; Hosseini BA; Giannini A; Boccuto A; Dragoni F; Vicenti I; Shafer RW; Zazzi M
J Antimicrob Chemother; 2021 Jan; 76(1):130-134. PubMed ID: 32974670
[TBL] [Abstract][Full Text] [Related]
12. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 RT nonnucleoside inhibitors and their interaction with RT for antiviral drug development.
Zhou Z; Lin X; Madura JD
Infect Disord Drug Targets; 2006 Dec; 6(4):391-413. PubMed ID: 17168804
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 reverse transcriptase and antiviral drug resistance. Part 1.
Das K; Arnold E
Curr Opin Virol; 2013 Apr; 3(2):111-8. PubMed ID: 23602471
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
[TBL] [Abstract][Full Text] [Related]
16. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients.
Clevenbergh P; Cua E; Dam E; Durant J; Schmit JC; Boulme R; Cottalorda J; Beyou A; Schapiro JM; Clavel F; Dellamonica P
HIV Clin Trials; 2002; 3(1):36-44. PubMed ID: 11819184
[TBL] [Abstract][Full Text] [Related]
18. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.
Hsiou Y; Ding J; Das K; Clark AD; Boyer PL; Lewi P; Janssen PA; Kleim JP; Rösner M; Hughes SH; Arnold E
J Mol Biol; 2001 Jun; 309(2):437-45. PubMed ID: 11371163
[TBL] [Abstract][Full Text] [Related]
19. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Balzarini J
Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549
[TBL] [Abstract][Full Text] [Related]
20. Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.
Brenner BG; Oliveira M; Ibanescu RI; Routy JP; Thomas R
J Antimicrob Chemother; 2023 Aug; 78(8):1921-1928. PubMed ID: 37303226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
